InvestorsHub Logo
Followers 10
Posts 1578
Boards Moderated 0
Alias Born 10/15/2014

Re: None

Tuesday, 03/21/2017 2:40:04 PM

Tuesday, March 21, 2017 2:40:04 PM

Post# of 16885
Zacks

They reduced the price target to $11 a share, but remain pretty bullish on Titan's future prospects.

Revenues were lower than expected due to the substantial upfront work required to develop the distribution systems, reimbursement and training required to commercialize Probuphine. As a result we lower our forward
estimates for Probuphine revenues to reflect the slower pace, which reduces our price target. Overall, expenses were slightly higher than our estimates, predominantly due to greater external research and development expenses for product development programs. Future upward revisions will depend heavily on the success of Braeburn's commercial launch and Titan s achievements of milestones for development projects.



http://s1.q4cdn.com/460208960/files/News/2017/March-21-2017_TTNP_Vandermosten.pdf








Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TTNP News